- Details
- Alicia Morgans and Emmanuel Antonarakis discuss an ongoing biomarker analysis aimed at identifying a molecular signature predictive of response in the COMBAT study. The COMBAT study is a multi-center, single-arm, open label Phase 2 study in asymptomatic patients with mCRPC who had soft tissue metastases amenable to biopsy, and who progressed on at least one prior novel AR-targeted therapy (and up...
|
- Details
- Josh Lang joins Alicia Morgans in a discussion on the importance of understanding mechanisms of resistance to targeted therapies through the development of novel liquid biopsies of the human tumor microenvironment. Lang highlights his research which looks beyond tissue biopsy to liquid biopsies of cancer cells from a blood draw to inform decision-making. Research funded by the Prostate Cancer Foun...
|
- Details
- Alicia Morgans converses with Neeraj Agarwal about the ongoing phase III Contact-02 Trial, designed for patients with metastatic castrate-resistant prostate cancer (CRPC) who show disease progression on a novel hormonal therapy or androgen receptor inhibitor. Patients eligible for this trial should have measurable disease, which may include extra pelvic lymphadenopathy or visceral metastasis. Dr....
|
- Details
- In this discussion, Neal Shore speaks with Alicia Morgans to discuss their experiences and insights on topics ranging from survivorship to new developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Morgans highlights her work in the EAU session on mCRPC, outlining the significance of PARP inhibitors, the PROpel and MAGNITUDE trials, and the potential role of...
|
- Details
- Rahul Aggarwal speaks with Alicia Morgans about the completed phase III trial AFT-19 for high-risk biochemically relapsed prostate cancer patients. The trial explored three arms: ADT alone, ADT plus apalutamide, and a triplet of ADT, apalutamide, and abiraterone, with a primary endpoint of PSA progression-free survival. Results showed significant prolongation of PSA progression-free survival in bo...
|
- Details
- In this discussion, Susan Slovin and Alicia Morgans discuss the incorporation of PSMA PET imaging and emerging treatments like lutetium-177-PSMA in genitourinary oncology. Referencing ASCO 2022 talks and clinical trials, particularly Dr. Mike Hofman's study comparing lutetium-PSMA and cabazitaxel post-docetaxel, they review three-year data showing no significant difference in overall survival betw...
|
- Details
- Alicia Morgans speaks with Oliver Sartor about the SPLASH trial and advances in radioligand therapy. The SPLASH trial involves PSMA I&T Lutetium-177 (renamed PNT2002) for pre-chemo, metastatic CRPC patients, with some differences in dose and schedule compared to PSMA 617. In the lead-in study involving 27 PSMA PET-selected patients, the initial PSA 50 response rate was 40%, and the radiographic re...
|
- Details
- Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...
|
- Details
- Vivek Narayan joins Alicia Morgans at ASCO 2022 to discuss his work with CAR T-cell therapies and prostate cancer, the first-in-human study. Using a low-dose escalation approach, Dr. Narayan and his team designed the study safety as the primary objective to evaluate the feasibility of manufacturing and delivering the CAR T-cells. He describes how findings showed both on-treatment toxicity and on-t...
|
- Details
- Alicia Morgans sits down with Charles Ryan to discuss the recent publication of Urologic Oncology: Multidisciplinary Care for Patients, a book she co-edited with Kelly Stratton. Dr. Morgans shares her thoughts on the importance of collaboration across teams in treating patients with GU cancers and provides an overview of key content in the book. Biographies: Alicia Morgans, MD, MPH , Genitourinary...
|
